VWA
CRSP icon

V Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

V Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,975
Closed -$221K – 489
2021
Q3 		$221K Hold
1,975
– – 0.03% 414
2021
Q2 		$318K Buy
1,975
+200
+11% +$24.3K 0.05% 353
2021
Q1 		$216K Buy
1,775
+100
+6% +$15.1K 0.04% 392
2020
Q4 		$256K Buy
+1,675
New +$198K 0.05% 327

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

V Wealth Advisors's CRSP Position: Q4 2021 in Review

V Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,975 shares — an estimated $221K sold.

V Wealth Advisors first reported a position in CRSP in Q4 2020 and held it in 4 quarters. The position peaked at $318K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • V Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • V Wealth Advisors sold 1,975 CRISPR Therapeutics shares in Q4 2021, an estimated $221K.
  • V Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 4 quarters.
  • V Wealth Advisors's CRISPR Therapeutics position peaked at $318K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on V Wealth Advisors's 13F filing for Q4 2021, filed 17 Feb 2022.